{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T17:25:43Z","timestamp":1792949143871,"version":"4.5.0"},"reference-count":140,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.ijantimicag.2019.05.003","type":"journal-article","created":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T12:51:49Z","timestamp":1557319909000},"page":"134-142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"title":["Ivermectin: From theory to clinical application"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7782-0774","authenticated-orcid":false,"given":"Dalia S.","family":"Ashour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0001","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.bj.2016.04.002","article-title":"Honoring antiparasitics: the 2015 Nobel Prize in Physiology or Medicine","volume":"39","author":"Chen","year":"2016","journal-title":"Biomed J"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0002","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1146\/annurev.en.36.010191.000515","article-title":"Avermectins, a novel class of compounds: implications for use in arthropod pest control","volume":"36","author":"Lasota","year":"1991","journal-title":"Annu Rev Entomol"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0003","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/j.1365-2583.2010.01017.x","article-title":"A point mutation in a glutamate-gated chloride channel confers abamectin resistance in the two-spotted spider mite, Tetranychus urticae Koch","volume":"19","author":"Kwon","year":"2010","journal-title":"Insect Molec Biol"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0004","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s11101-010-9168-y","article-title":"Use of natural products in the crop protection industry","volume":"10","author":"H\u00fcter","year":"2011","journal-title":"Phytochem Rev"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0005","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1208\/s12248-007-9000-9","article-title":"The pharmacokinetics and interactions of ivermectin in humans\u2014a mini-review","volume":"10","author":"Gonz\u00e1lez Canga","year":"2008","journal-title":"AAPS J"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0006","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.pt.2014.07.005","article-title":"Ivermectin: panacea for resource-poor communities?","volume":"30","author":"Omura","year":"2014","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0007","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.pt.2017.02.004","article-title":"Ivermectin\u2014old drug, new tricks?","volume":"33","author":"Laing","year":"2017","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0008","unstructured":"MOXIDECTIN tablets, for oral use Melbourne. Victoria, Australia: Medicines Development for Global Health; 2018 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210867lbl.pdf. [Accessed 10 January 2018]."},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0009","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijantimicag.2007.08.023","article-title":"Ivermectin: 25 years and still going strong","volume":"31","author":"Omura","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0010","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.6308762","article-title":"Ivermectin: a potent new antiparasitic agent","volume":"221","author":"Campbell","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0011","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/ja.2017.11","article-title":"Ivermectin: enigmatic multifaceted \u2018wonder\u2019 drug continues to surprise and exceed expectations","volume":"70","author":"Crump","year":"2017","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0012","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1086\/430827","article-title":"Treatment of human disseminated strongyloidiasis with a parenteral veterinary formulation of ivermectin","volume":"41","author":"Marty","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0013","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/004982598239597","article-title":"Identification of cytochrome P4503A4 as the major enzyme responsible for the metabolism of ivermectin by human liver microsomes","volume":"28","author":"Zeng","year":"1998","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0014","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1242\/jeb.118570","article-title":"Characterization of the target of ivermectin, the glutamate-gated chloride channel, from Anopheles gambiae","volume":"218","author":"Meyers","year":"2015","journal-title":"J Exp Biol"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0015","doi-asserted-by":"crossref","first-page":"e1883","DOI":"10.1371\/journal.pntd.0001883","article-title":"Relative neurotoxicity of ivermectin and moxidectin in Mdr1ab (\u2013\/\u2013) mice and effects on mammalian GABA(A) channel activity","volume":"6","author":"Menez","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0016","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ijpddr.2011.10.002","article-title":"A reappraisal of the relative sensitivity of nematode pharyngeal and somatic musculature to macrocyclic lactone drugs","volume":"2","author":"Kotze","year":"2012","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0017","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1179\/000349809X12459740922138","article-title":"Toxicity of blood meals from ivermectin-treated cattle to Anopheles gambiae s.l","volume":"103","author":"Fritz","year":"2009","journal-title":"Ann Trop Med Parasitol"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0018","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1007\/s00436-005-0099-2","article-title":"Effects of parasitic helminths and ivermectin treatment on clinical parameters in the European wild boar (Sus scrofa)","volume":"98","author":"Lopez-Olvera","year":"2006","journal-title":"Parasitol Res"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0019","doi-asserted-by":"crossref","first-page":"20120","DOI":"10.1073\/pnas.1011983107","article-title":"Ivermectin disrupts the function of the excretory\u2013secretory apparatus in microfilariae of Brugia malayi","volume":"107","author":"Moreno","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0020","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s13071-017-2116-6","article-title":"Examining the role of macrolides and host immunity in combatting filarial parasites","volume":"10","author":"Carithers","year":"2017","journal-title":"Parasit Vectors"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0021","doi-asserted-by":"crossref","first-page":"e2939","DOI":"10.1371\/journal.pntd.0002939","article-title":"Proteomic analysis of adult Ascaris suum fluid compartments and secretory products","volume":"8","author":"Chehayeb","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0022","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10158-016-0190-7","article-title":"How do the macrocyclic lactones kill filarial nematode larvae?","volume":"16","author":"Wolstenholme","year":"2016","journal-title":"Invert Neurosci"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0023","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1016\/j.lfs.2007.02.025","article-title":"Effect of ivermectin on the cellular and humoral immune responses of rabbits","volume":"80","author":"Sajid","year":"2007","journal-title":"Life Sci"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0024","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1365-2249.1993.tb03452.x","article-title":"Neutrophil activation in ivermectin-treated onchocerciasis patients","volume":"94","author":"Njoo","year":"1993","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0025","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/infdis\/170.3.663","article-title":"C-reactive protein and interleukin-6 are elevated in onchocerciasis patients after ivermectin treatment","volume":"170","author":"Njoo","year":"1994","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0026","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.vetpar.2014.02.004","article-title":"Ivermectin-dependent attachment of neutrophils and peripheral blood mononuclear cells to Dirofilaria immitis microfilariae in vitro","volume":"206","author":"Vatta","year":"2014","journal-title":"Vet Parasitol"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0027","doi-asserted-by":"crossref","first-page":"246","DOI":"10.4269\/ajtmh.2006.74.246","article-title":"Impairment of host immune response against Strongyloides stercoralis by human T cell lymphotropic virus type 1 infection","volume":"74","author":"Hirata","year":"2006","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0028","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.bmc.2008.12.003","article-title":"Ivermectin-derived leishmanicidal compounds","volume":"17","author":"dos Santos","year":"2009","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0029","doi-asserted-by":"crossref","first-page":"e412","DOI":"10.1371\/journal.pntd.0000412","article-title":"Neglected tropical diseases in sub-Saharan Africa: review of their prevalence, distribution, and disease burden","volume":"3","author":"Hotez","year":"2009","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0030","first-page":"594","article-title":"Global Programme to Eliminate Lymphatic Filariasis: progress report, 2016","volume":"92","year":"2017","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0031","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006944","article-title":"The prevalence of lymphatic filariasis infection and disease following six rounds of mass drug administration in Mandalay Region, Myanmar","volume":"12","author":"Dickson","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0032","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.ijpara.2004.04.010","article-title":"An ivermectin-sensitive glutamate-gated chloride channel subunit from Dirofilaria immitis","volume":"34","author":"Yates","year":"2004","journal-title":"Int J Parasitol"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0033","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1371\/journal.pntd.0000317","article-title":"The Global Program To Eliminate Lymphatic Filariasis: health impact after 8 years","volume":"2","author":"Ottesen","year":"2008","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0034","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1365-2885.2006.00780.x","article-title":"Fumagillin, a new P-glycoprotein-interfering agent able to modulate moxidectin efflux in rat hepatocytes","volume":"29","author":"Dupuy","year":"2006","journal-title":"J Vet Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0035","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.ijpara.2008.03.002","article-title":"Combined ivermectin and doxycycline treatment has microfilaricidal and adulticidal activity against Dirofilaria immitis in experimentally infected dogs","volume":"38","author":"Bazzocchi","year":"2008","journal-title":"Int J Parasitol"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0036","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.vetpar.2015.02.023","article-title":"Doxycycline levels and anti-Wolbachia antibodies in sera from dogs experimentally infected with Dirofilaria immitis and treated with a combination of ivermectin\/doxycycline","volume":"209","author":"Menozzi","year":"2015","journal-title":"Vet Parasitol"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0037","doi-asserted-by":"crossref","first-page":"23458","DOI":"10.1038\/srep23458","article-title":"Minocycline as a re-purposed anti-Wolbachia macrofilaricide: superiority compared with doxycycline regimens in a murine infection model of human lymphatic filariasis","volume":"6","author":"Sharma","year":"2016","journal-title":"Sci Rep"},{"issue":"Suppl 2","key":"10.1016\/j.ijantimicag.2019.05.003_bib0038","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1179\/000349802125002374","article-title":"Lymphatic filariasis elimination: progress in global programme development","volume":"96","author":"Molyneux","year":"2002","journal-title":"Ann Trop Med Parasitol"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0039","unstructured":"World Health Organization (WHO). Global Programme to Eliminate Lymphatic Filariasis. Geneva, Switzerland: WHO. http:\/\/www.who.int\/lymphatic_filariasis\/elimination-programme\/en\/ [Accessed 25 May 2018]."},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005163","article-title":"Potential value of triple drug therapy with ivermectin, diethylcarbamazine, and albendazole (IDA) to accelerate elimination of lymphatic filariasis and onchocerciasis in Africa","volume":"11","author":"Fischer","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0041","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1086\/383326","article-title":"Incidence of blindness during the Onchocerciasis Control Programme in western Africa, 1971\u20132002","volume":"189","author":"Little","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0042","unstructured":"World Health Organization (WHO). Onchocerciasis. Geneva, Switzerland: WHO. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/onchocerciasis [Accessed 30 May 2019]."},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0043","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0065-308X(05)61010-X","article-title":"Lymphatic filariasis: treatment, control and elimination","volume":"61","author":"Ottesen","year":"2006","journal-title":"Adv Parasitol"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0044","doi-asserted-by":"crossref","first-page":"e2824","DOI":"10.1371\/journal.pntd.0002824","article-title":"Reproductive status of Onchocerca volvulus after ivermectin treatment in an ivermectin-na\u00efve and a frequently treated population from Cameroon","volume":"8","author":"Nana-Djeunga","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0045","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.actatropica.2015.03.019","article-title":"Conventional parasitology and DNA-based diagnostic methods for onchocerciasis elimination programmes","volume":"146","author":"Lloyd","year":"2015","journal-title":"Acta Trop"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0046","doi-asserted-by":"crossref","first-page":"e1825","DOI":"10.1371\/journal.pntd.0001825","article-title":"Proof-of-principle of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: final results of a study in Mali and Senegal","volume":"6","author":"Traore","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0047","unstructured":"World Health Organization (WHO). Onchocerciasis. Geneva, Switzerland; WHO. http:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/onchocerciasis [Accessed 25 May 2018]."},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0048","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1128\/CMR.00057-10","article-title":"Onchocerciasis: the role of Wolbachia bacterial endosymbionts in parasite biology, disease pathogenesis, and treatment","volume":"24","author":"Tamarozzi","year":"2011","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"10.1016\/j.ijantimicag.2019.05.003_bib0049","article-title":"Doxycycline plus ivermectin versus ivermectin alone for treatment of patients with onchocerciasis","author":"Abegunde","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0050","doi-asserted-by":"crossref","first-page":"e3018","DOI":"10.1371\/journal.pntd.0003018","article-title":"Strongyloidiasis\u2014an insight into its global prevalence and management","volume":"8","author":"Puthiyakunnon","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0051","unstructured":"World Health Organization (WHO). Strongyloidiasis. Geneva, Switzerland; WHO. https:\/\/www.who.int\/intestinal_worms\/epidemiology\/strongyloidiasis\/en\/ [Accessed 16 February 2019]."},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0052","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0304-4017(01)00472-1","article-title":"Nematocidal activities of thiabendazole and ivermectin against the larvae of Strongyloides ratti and S. venezuelensis","volume":"99","author":"Satou","year":"2001","journal-title":"Vet Parasitol"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0053","doi-asserted-by":"crossref","first-page":"453","DOI":"10.4269\/ajtmh.2003.68.453","article-title":"Case report: Rectal administration of ivermectin to a patient with Strongyloides hyperinfection syndrome","volume":"68","author":"Tarr","year":"2003","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0054","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1007\/s00134-005-2725-y","article-title":"Successful use of parenteral ivermectin in an immunosuppressed patient with disseminated strongyloidiasis and septic shock","volume":"31","author":"Salluh","year":"2005","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0055","unstructured":"Merck & Co. Stromectol\u00ae. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/98\/50-742s001_Stromectol_PrntLbl.pdf [Accessed 17 April 2018]."},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0056","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1345\/aph.1K302","article-title":"Manifestations, diagnosis, and treatment of Strongyloides stercoralis infection","volume":"41","author":"Segarra-Newnham","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0057","first-page":"531","article-title":"Disseminated strongyloidiasis successfully treated with extended duration ivermectin combined with albendazole: a case report of intractable strongyloidiasis","volume":"35","author":"Pornsuriyasak","year":"2004","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0058","first-page":"1","article-title":"Human trichinellosis caused by Trichinella britovi in Greece, and literature review","volume":"13","author":"Dimzas","year":"2019","journal-title":"J Helminthol"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0059","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.vetpar.2007.07.002","article-title":"World distribution of Trichinella spp. infections in animals and humans","volume":"149","author":"Pozio","year":"2007","journal-title":"Vet Parasitol"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0060","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40249-015-0070-0","article-title":"Malaria endemicity and co-infection with tissue-dwelling parasites in sub-Saharan Africa: a review","volume":"4","author":"Onkoba","year":"2015","journal-title":"Infect Dis Poverty"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0061","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/pmj.78.915.15","article-title":"New aspects of human trichinellosis: the impact of new Trichinella species","volume":"78","author":"Bruschi","year":"2002","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0062","doi-asserted-by":"crossref","first-page":"86","DOI":"10.5152\/tpd.2011.22","article-title":"Therapeutic efficacy of dormectin, ivermectin and levamisole against different stages of Trichinella spiralis in rats","volume":"35","author":"Soliman","year":"2011","journal-title":"Turkiye Parazitol Derg"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0063","first-page":"193","article-title":"Infectivity of ivermectin-treated Trichinella spiralis larvae: a new challenge for control","volume":"6","author":"Shoheib","year":"2013","journal-title":"PUJ"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0064","first-page":"2009","article-title":"Head lice","author":"Burgess","year":"2009","journal-title":"BMJ Clin Evid"},{"issue":"2","key":"10.1016\/j.ijantimicag.2019.05.003_bib0065","first-page":"44","article-title":"Pediculosis: current aspects of the old problem [in Russian]","author":"Lopatina","year":"2015","journal-title":"Med Parazitol (Mosk)"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0066","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1542\/peds.110.3.638","article-title":"Head lice","volume":"110","author":"Frankowski","year":"2002","journal-title":"Pediatrics"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0067","first-page":"985","article-title":"Oral ivermectin for head lice: a comparison with 0.5% topical malathion lotion","volume":"8","author":"Nofal","year":"2010","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0068","first-page":"967","article-title":"Topical ivermectin lotion for head lice","volume":"368","author":"Pariser","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0069","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1086\/499279","article-title":"Oral ivermectin in the treatment of body lice","volume":"193","author":"Foucaulf","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0070","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1603\/ME11051","article-title":"Ivermectin acts as a posteclosion nymphicide by reducing blood feeding of human head lice (Anoplura: Pediculidae) that hatched from treated eggs","volume":"48","author":"Strycharz","year":"2011","journal-title":"J Med Entomol"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0071","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1365-2583.2011.01097.x","article-title":"Brief exposures of human body lice to sublethal amounts of ivermectin over-transcribes detoxification genes involved in tolerance","volume":"20","author":"Yoon","year":"2011","journal-title":"Insect Mol Biol"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0072","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1097\/INF.0b013e3181e63f5f","article-title":"Oral ivermectin for treatment of pediculosis capitis","volume":"29","author":"Ameen","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0073","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa0905471","article-title":"Oral ivermectin versus malathion lotion for difficult-to-treat head lice","volume":"362","author":"Chosidow","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0074","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/pde.12982","article-title":"Management of head louse infestations in the United States\u2014a literature review","volume":"33","author":"Koch","year":"2016","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0075","doi-asserted-by":"crossref","first-page":"E50","DOI":"10.1111\/j.1749-6632.2011.06364.x","article-title":"Scabies in animals and humans: history, evolutionary perspectives, and modern clinical management","volume":"1230","author":"Currier","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0076","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/S0140-6736(12)61729-2","article-title":"Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990\u20132010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Vos","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0077","series-title":"Difficult-to-treat scabies: oral ivermectin. Evidence summary [ESUOM29]","year":"2014"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0078","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1201-9712(98)90118-7","article-title":"Ivermectin for Sarcoptes scabiei hyperinfestation","volume":"2","author":"Huffam","year":"1998","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0079","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1046\/j.1365-2133.2000.03480.x","article-title":"Ivermectin alone or in combination with benzyl benzoate in the treatment of human immunodeficiency virus-associated scabies","volume":"142","author":"Alberici","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0080","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/j.1468-3083.2009.03177.x","article-title":"Variable response of crusted scabies to oral ivermectin: report on eight Egyptian patients","volume":"23","author":"Nofal","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0081","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3122\/jabfm.2017.01.160190","article-title":"Epidemiology, diagnosis, and treatment of scabies in a dermatology office","volume":"30","author":"Anderson","year":"2017","journal-title":"J Am Board Fam Med"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0082","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/1346-8138.12728","article-title":"Experimental study of pharmacokinetics of external, whole-body bathing application of ivermectin","volume":"42","author":"Miyajima","year":"2015","journal-title":"J Dermatol"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0083","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004151","article-title":"Impact of an ivermectin mass drug administration on scabies prevalence in a remote Australian aboriginal community","volume":"9","author":"Kearns","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0084","article-title":"Orbital myiasis: due to invasion of larvae of flesh fly (Wohlfahrtia magnifica) in a child; rare presentation","volume":"2012","author":"Maurya","year":"2012","journal-title":"Case Rep Ophthalmol Med"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0085","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1590\/S0103-64402004000100015","article-title":"Oral myiasis treated with ivermectin: case report","volume":"15","author":"Shinohara","year":"2004","journal-title":"Braz Dent J"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0086","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1086\/507038","article-title":"Role of ivermectin in the treatment of severe orbital myiasis due to Cochliomyia hominivorax","volume":"43","author":"Osorio","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0087","article-title":"A case of orbital myiasis in recurrent eyelid basal cell carcinoma invasive into the orbit","volume":"2016","author":"Pandey","year":"2016","journal-title":"Case Rep Ophthalmol Med"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0088","doi-asserted-by":"crossref","first-page":"225","DOI":"10.4103\/0301-4738.95880","article-title":"Ivermectin treatment for massive orbital myiasis in an empty socket with concomitant scalp pediculosis","volume":"60","author":"Puthran","year":"2012","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0089","first-page":"41","article-title":"Tratamiento de miasis oral con ivermectina. Notificaci\u00f3n de tres casos causados por Cochliomyia hominivorax (Coquerel) [Treatment of oral myiasis with ivermectin. Notification of three cases caused by Cochliomyia hominivorax (Coquerel)]","volume":"10","author":"Duque","year":"1998","journal-title":"Rev Fac Odontol Univ Ant"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0090","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s12936-017-1801-4","article-title":"Ivermectin to reduce malaria transmission I. Pharmacokinetic and pharmacodynamic considerations regarding efficacy and safety","volume":"16","author":"Chaccour","year":"2017","journal-title":"Malar J"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0091","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1093\/infdis\/jis184","article-title":"Drug screen targeted at Plasmodium liver stages identifies a potent multistage antimalarial drug","volume":"205","author":"da Cruz","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0092","series-title":"64th Annual Meeting of the American Society of Tropical Medicine and Hygiene; 25\u201329 October 2015","article-title":"Ivermectin inhibits the development of Plasmodium vivax in Anopheles dirus","author":"Kobylinski","year":"2015"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0093","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1186\/s12864-015-2029-8","article-title":"Age and prior blood feeding of Anopheles gambiae influences their susceptibility and gene expression patterns to ivermectin-containing blood meals","volume":"16","author":"Seaman","year":"2015","journal-title":"BMC Genomics"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0094","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.actatropica.2010.06.001","article-title":"The effect of oral anthelmintics on the survivorship and re-feeding frequency of anthropophilic mosquito disease vectors","volume":"116","author":"Kobylinski","year":"2010","journal-title":"Acta Trop"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0095","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.actatropica.2011.10.007","article-title":"Comparative evaluation of systemic drugs for their effects against Anopheles gambiae","volume":"121","author":"Butters","year":"2012","journal-title":"Acta Trop"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0096","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.2174\/138920112800399248","article-title":"Ivermectin in human medicine, an overview of the current status of its clinical applications","volume":"13","author":"Gonz\u00e1lez","year":"2012","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0097","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2183\/pjab.87.13","article-title":"Ivermectin, \u2018wonder drug\u2019 from Japan: the human use perspective","volume":"87","author":"Crump","year":"2011","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0098","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1016\/0140-6736(90)93187-T","article-title":"Pregnancy outcome after inadvertent ivermectin treatment during community-based distribution","volume":"336","author":"Pacque","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0099","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000293923","article-title":"New ventures in the genotoxic and cytotoxic effects of macrocyclic lactones, abamectin and ivermectin","volume":"128","author":"Molinari","year":"2010","journal-title":"Cytogenet Genome Res"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0100","series-title":"Preventive chemotherapy in human helminthiasis. Coordinated use of anthelminthic drugs in control interventions. A manual for health professionals and programme managers","year":"2016"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0101","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1292\/jvms.10-0424","article-title":"Central and peripheral neurotoxic effects of ivermectin in rats","volume":"73","author":"Trailovic","year":"2011","journal-title":"J Vet Med Sci"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0102","doi-asserted-by":"crossref","first-page":"382","DOI":"10.4269\/ajtmh.17-0042","article-title":"Serious neurological adverse events after ivermectin\u2014do they occur beyond the indication of onchocerciasis?","volume":"98","author":"Chandler","year":"2017","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0103","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0140-6736(96)11094-1","article-title":"Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection","volume":"350","author":"Gardon","year":"1997","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.ijantimicag.2019.05.003_bib0104","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1186\/1475-2883-2-S1-S4","article-title":"Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon","volume":"2","author":"Boussinesq","year":"2003","journal-title":"Filaria J"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0105","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s40801-017-0110-0","article-title":"Central and peripheral nervous system disorders following ivermectin mass administration: a descriptive study based on the Democratic Republic of Congo pharmacovigilance system","volume":"4","author":"Nzolo","year":"2017","journal-title":"Drugs Real World Outcomes"},{"issue":"Suppl 1","key":"10.1016\/j.ijantimicag.2019.05.003_bib0106","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/1475-2883-2-S1-S5","article-title":"Possible pathogenic pathways in the adverse clinical events seen following ivermectin administration to onchocerciasis patients","volume":"2","author":"Mackenzie","year":"2003","journal-title":"Filaria J"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0107","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.trstmh.2003.10.018","article-title":"Adverse systemic reactions to treatment of onchocerciasis with ivermectin at normal and high doses given annually or three-monthly","volume":"98","author":"Kamgno","year":"2004","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0108","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S0190-9622(00)90131-2","article-title":"A comparative study of oral ivermectin and topical permethrin cream in the treatment of scabies","volume":"42","author":"Usha","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0109","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1017\/S002202990400038X","article-title":"Comparative depletion of ivermectin and moxidectin milk residues in dairy sheep after oral and subcutaneous administration","volume":"71","author":"Imperiale","year":"2004","journal-title":"J Dairy Res"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0110","doi-asserted-by":"crossref","first-page":"9733","DOI":"10.1021\/jf071941z","article-title":"Kinetics of abamectin disposition in blood plasma and milk of lactating dairy sheep and suckling lambs","volume":"55","author":"Cerkvenik-Flajs","year":"2007","journal-title":"J Agric Food Chem"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0111","doi-asserted-by":"crossref","first-page":"987","DOI":"10.2174\/138920112800399121","article-title":"Ivermectin residue depletion in food producing species and its presence in animal foodstuffs with a view to human safety","volume":"13","author":"Escribano","year":"2012","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0112","first-page":"288","article-title":"Determinants of parasite drug resistance in human lymphatic filariasis","volume":"29","author":"Cobo","year":"2016","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0113","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1128\/AAC.00713-16","article-title":"Acquired tolerance to ivermectin and moxidectin after drug selection pressure in the nematode Caenorhabditis elegans","volume":"60","author":"M\u00e9nez","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0114","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0001-706X(02)00117-1","article-title":"Immunocompetence may be important in the effectiveness of Mectizan (ivermectin) in the treatment of human onchocerciasis","volume":"84","author":"Ali","year":"2002","journal-title":"Acta Trop"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0115","doi-asserted-by":"crossref","first-page":"e2084","DOI":"10.1371\/journal.pntd.0002084","article-title":"Dynamics of Onchocerca volvulus microfilarial densities after ivermectin treatment in an ivermectin-naive and a multiply treated population from Cameroon","volume":"7","author":"Pion","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0116","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1179\/000349804225003253","article-title":"An investigation of persistent microfilaridermias despite multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana","volume":"98","author":"Awadzi","year":"2004","journal-title":"Ann Trop Med Parasitol"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0117","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jgar.2015.08.004","article-title":"Monitoring the efficacy of drugs for neglected tropical diseases controlled by preventive chemotherapy","volume":"3","author":"Albonico","year":"2015","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0118","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/S0140-6736(07)60942-8","article-title":"Prevalence and intensity of Onchocerca volvulus infection and efficacy of ivermectin in endemic communities in Ghana: a two-phase epidemiological study","volume":"369","author":"Osei-Atweneboana","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0119","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0304-4017(01)00551-9","article-title":"Selection for resistance to macrocyclic lactones by Haemonchus contortus in sheep","volume":"103","author":"Ranjan","year":"2002","journal-title":"Vet Parasitol"},{"issue":"Suppl 2","key":"10.1016\/j.ijantimicag.2019.05.003_bib0120","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1186\/1756-3305-2-S2-S4","article-title":"Faecal cyathostomin egg count distribution and efficacy of anthelmintics against cyathostomins in Italy: a matter of geography?","volume":"2","author":"Milillo","year":"2009","journal-title":"Parasit Vectors"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0121","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1517\/phgs.4.4.397.22747","article-title":"Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs","volume":"4","author":"Sakaeda","year":"2003","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0122","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.molbiopara.2007.11.017","article-title":"P-glycoprotein-like protein, as possible genetic marker for ivermectin resistance selection in Onchocerca volvulus","volume":"158","author":"Bourguinat","year":"2008","journal-title":"Mol Biochem Parasitol"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0123","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1073\/pnas.97.6.2674","article-title":"The genetics of ivermectin resistance in Caenorhabditis elegans","volume":"97","author":"Dent","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0124","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.ijpara.2014.08.005","article-title":"A dyf-7 haplotype causes sensory neuron defects and is associated with macrocyclic lactone resistance worldwide in the nematode parasite Haemonchus contortus","volume":"44","author":"Urdaneta-Marquez","year":"2014","journal-title":"Int J Parasitol"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005816","article-title":"Genome-wide analysis of ivermectin response by Onchocerca volvulus reveals that genetic drift and soft selective sweeps contribute to loss of drug sensitivity","volume":"11","author":"Doyle","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0126","doi-asserted-by":"crossref","first-page":"D774","DOI":"10.1093\/nar\/gkv1217","article-title":"WormBase 2016: expanding to enable helminth genomic research","volume":"44","author":"Howe","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0127","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3109\/10611860903450007","article-title":"Improvement in the antifilarial efficacy of doxycycline and rifampicin by combination therapy and drug delivery approach","volume":"18","author":"Dangi","year":"2010","journal-title":"J Drug Target"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0128","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/wnan.143","article-title":"Overcoming in vivo barriers to targeted nanodelivery","volume":"3","author":"Chrastina","year":"2011","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0129","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00436-013-3696-5","article-title":"Therapeutic efficacy of poly (lactic-co-glycolic acid) nanoparticles encapsulated ivermectin (nano-ivermectin) against brugian filariasis in experimental rodent model","volume":"113","author":"Ali","year":"2014","journal-title":"Parasitol Res"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0130","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/10611860500285439","article-title":"Use of liposomized tetracycline in elimination of Wolbachia endobacterium of human lymphatic filariid Brugia malayi in a rodent model","volume":"13","author":"Bajpai","year":"2005","journal-title":"J Drug Target"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0131","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/10611860310001620707","article-title":"Immunomodulator tuftsin augments antifilarial activity of diethylcarbamazine against experimental brugian filariasis","volume":"11","author":"Owais","year":"2003","journal-title":"J Drug Target"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0132","first-page":"297","article-title":"Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential","volume":"1","author":"Immordino","year":"2006","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0133","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1517\/17425247.2013.771630","article-title":"Nanopharmaceuticals to target antifilarials: a comprehensive review","volume":"10","author":"Ali","year":"2013","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0134","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/8043983","article-title":"Liposomal systems as nanocarriers for the antiviral agent ivermectin","volume":"2016","author":"Croci","year":"2016","journal-title":"Int J Biomater"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0135","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3109\/02652048.2010.501397","article-title":"Ivermectin-loaded microparticles for parenteral sustained release: in vitro characterization and effect of some formulation variables","volume":"27","author":"Camargo","year":"2010","journal-title":"J Microencapsul"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0136","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004173","article-title":"Polyanhydride nanoparticle delivery platform dramatically enhances killing of filarial worms","volume":"9","author":"Binnebose","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0137","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1007\/s00436-013-3466-4","article-title":"Improved antifilarial activity of ivermectin in chitosan\u2013alginate nanoparticles against human lymphatic filarial parasite, Brugia malayi","volume":"112","author":"Ali","year":"2013","journal-title":"Parasitol Res"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0138","doi-asserted-by":"crossref","first-page":"S201","DOI":"10.1016\/j.toxlet.2015.08.602","article-title":"Lipid nanoparticles as carrier systems for ivermectin and methoprene aiming veterinary applications","volume":"238","author":"Faria Cola","year":"2015","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0139","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1007\/s00436-017-5510-2","article-title":"Ivermectin lipid-based nanocarriers as novel formulations against head lice","volume":"116","author":"Ullio-Gamboa","year":"2017","journal-title":"Parasitol Res"},{"key":"10.1016\/j.ijantimicag.2019.05.003_bib0140","doi-asserted-by":"crossref","first-page":"10190","DOI":"10.1002\/anie.201602164","article-title":"A splendid gift from the earth: the origins and impact of the avermectins (Nobel Lecture)","volume":"55","author":"Omura","year":"2016","journal-title":"Angew Chem Int Ed Engl"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857919301104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857919301104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:33:49Z","timestamp":1760376829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857919301104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":140,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0924857919301104"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.05.003","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ivermectin: From theory to clinical application","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}